# Choice

# TATA Elxsi Limited

April 01, 2025 | CMP: INR 5,215 | Target Price: INR 4,900

Expected Share Price Return: -6.0% | Dividend Yield: 1.3% | Expected Total Return: -4.7%



Change in Estimates	<b>~</b>
Change in Target Price	<b>✓</b>
Change in Recommendation	<b>/</b>
Company Info	
BB Code	TELX IN EQUITY
Face Value (INR)	10.0
52 W High/Low (INR)	9,083/5,160
Mkt Cap (Bn)	INR 326.7/ \$3.8
Shares o/s (Mn)	62.3
3M Avg. Daily Volume	29,206


Change in CEBPL Estimates							
	FY26E FY27E						
INR Bn	New	Old	Dev. (%)	New	Old	Dev. (%)	
Revenues	40.5	46.0	(12.0)	45.5	54.9	(17.2)	
GPM (%)	40.7	41.3	(67) bps	41.2	42.0	(79) bps	
EBIT	10.5	12.3	(14.8)	12.1	15.2	(20.7)	
EBITM %	25.9	26.7	(85) bps	26.5	27.6	(117) bps	
EPS	142.6	166.9	(14.6)	163.2	205.4	(20.6)	

Actual vs CEBPL								
INR Bn	Q3FY25A	CEBPL	Dev.%					
Revenue	9.3	9.9	(5.4)					
EBIT	2.2	2.6	(15.5)					
EBITM %	23.5	26.3	(281) Bps					
PAT	1.9	2.2	(9.7)					

Key Financials							
INR Bn	FY23	FY24	FY25E	FY26E	FY27E		
Revenue	31.4	35.5	37.7	40.5	45.5		
YoY (%)	27.3	13.0	6.3	7.3	12.4		
EBIT	8.8	9.5	9.1	10.5	12.1		
EBITM %	28.0	26.7	24.2	25.9	26.5		
Adj PAT	7.6	7.9	8.1	8.9	10.2		
EPS	121.3	127.2	129.7	142.6	163.2		
ROE %	36.2	31.6	29.4	29.5	30.6		
ROCE %	38.0	34.0	30.2	31.8	33.5		
PE(x)	43.0	41.0	40.2	36.6	32.0		

Shareholding Pattern (%)						
Dec-24	Sep-24	Jun-24				
43.91	43.91	43.92				
13.27	13.65	13.67				
7.50	7.38	6.24				
35.30	35.10	36.20				
	<b>Dec-24</b> 43.91 13.27	Dec-24         Sep-24           43.91         43.91           13.27         13.65           7.50         7.38				

Relative Performance (%)							
YTD	3Y	2Y	1Y				
BSE IT	2.2	32.4	3.7				
TELX	(40.0)	(9.1)	(29.4)				



#### **Rushil Katiyar**

Email: rushil.katiyar@choiceindia.com

Ph: +91 22 6707 9887

## Assessing Q3 Results amid Trump Tariffs & Macroeconomic Challenges TELX missed estimates by substantial margins.

- Revenue for Q3FY25 came at INR 9.3Bn up 2.7% YoY but down 1.7% QoQ (vs CEBPL est. at INR 9.9Bn).
- EBIT for Q3FY25 came at INR 2.2Bn, down 9.8% YoY and 7.8% QoQ (vs CEBPL est. at INR 2.6Bn). EBIT margin was down 327bps YoY and 156bps QoQ to 23.5% (vs CEBPL est. at 26.8%).
- PAT for Q3FY25 stood at INR 1.9Bn, down 3.6% YoY and 13.3% QoQ (vs CEBPL est, at INR 2,2Bn).

#### **Growth Hinges on Transportation Segment Amid Market Struggles:**

- TELX's Q3FY25 performance shows mixed results across its verticals and geographies. Overall growth across segments remained flattish, Transportation business grew 0.5% QoQ in CC, though impacted by weaker automotive demand in Europe & US, & remains the largest revenue contributor at 55%. Media & Communications saw a 0.4% QoQ growth in CC, while Healthcare & Life sciences grew 1.1% QoQ in CC, driven by new customer wins & traction in digital and Gen Al offerings, contributing 11.8% to revenue. Looking ahead, near-term outlook appears weak, primarily due to challenging demand environment in Transportation segment.
- The rise of Chinese EV manufacturers is reshaping the global automotive market, impacting TELX, whose revenue heavily depends on the transportation sector. As Chinese EVs gain market share, Western OEMs in China face declining profitability, prompting them to rethink strategies, cut R&D budgets, and refocus on ICE and hybrid vehicles. This slowdown directly affects TELX's transportation business, reflected in modest QoQ growth. In response, TELX is diversifying geographically, with strong growth in India, Japan, and emerging markets. Additionally, TELX is investing in innovative solutions such as the AVENIR SDV platform with Qualcomm, expanding into commercial vehicles, avionics, and defense, while utilizing global OEM partnerships to indirectly engage with China. However, we expect these strategic efforts to take time before they largely impact the company's performance.

Potential slowdown in IT spends amid Trump tariffs poses risk for TELX: TELX may face revenue challenges due to uncertainty over Trump-era tariffs, impacting European auto companies and TELX's revenue. With 30% of revenue from the US and 40% from Europe, any reduction in IT spending or delays in contracts could slow growth. Currency volatility poses margin risks, but stable tariffs may boost demand.

Q3FY25 EBIT margin drops to 23.5%, Plans recovery with improved efficiency and top-line growth: In Q3FY25, TELX reported an EBIT margin of 23.5%, down from 25.1% in Q2FY25 and 26.8% in Q3FY24. The decline was primarily due to adverse currency movements in EUR, GBP, and JPY (140bps impact) and wage hikes (100bps). However, operational efficiency and reduced on-site salary costs partially offset these effects. The attrition rate remained low at 12.4%. TELX aims to return to an EBIT margin of 25-26% through improved top-line growth, better billability, and utilization, following the completion of the wage hike cycle.

View and Valuation: TELX's performance fell short of expectations, with broad weaknesses across business segments. Healthcare saw slight improvement, but Transportation and Media remained weak. Delayed growth from recent deals hindered progress, with Transportation challenges expected to persist. Media & Communications and Healthcare may contribute more significantly starting H2FY26E. Additionally, the impact of Trump tariffs and increasing competitive pressures from China should be closely monitored. Given these factors, we've reduced our revenue estimates by 12-17%, downgraded our rating to HOLD, and lowered the target price to INR4,900, reflecting a reduced PE multiple of 30x (earlier 46x) due to a weaker outlook compared to peers in our coverage based on FY27E EPS of INR 163.2.

TATA Elxsi Ltd.	Q3 FY25	Q3 FY24	YoY (%)	Q2 FY25	QoQ (%)
Revenues (INR Mn)	9,392	9,142	2.7	9,551	(1.7)
Employee Cost	5,713	5,403	5.7	5,743	(0.5)
Gross Profit (INR Mn)	3,679	3,739	(1.6)	3,808	(3.4)
Gross Margin (%)	39.2	40.9	(173) bps	39.9	(70) bps
Other Cost	1213	1038	16.9	1144	6.0
Depreciation	260	255	2.0	272	(4.4)
EBIT (INR Mn)	2,206	2,447	(9.8)	2,393	(7.8)
EBIT Margin (%)	23.5	26.8	(327) bps	25.1	(156) bps
Other Income	399	349	14.1	643	(38.0)
Interest	47	56	(16.2)	48	(4.1)
PBT	2,558	2,741	(6.7)	2,987	(14.3)
Tax	568	676	(16.0)	693	(17.9)
PAT (INR Mn)	1,990	2,064	(3.6)	2,294	(13.3)
Basic EPS (INR)	32.0	33.2	(3.6)	36.8	(13.3)
Source: Company, CEBPL					


## **Management Call - Highlights**

- TELX launched its AVENIR SDV software suite at CES 2025 in partnership with Qualcomm. This platform is seen as a key offering to help global OEMs accelerate their software-defined vehicle and future mobility roadmaps.
- The company secured several multi-year, multi-million deals across verticals, including a significant deal with a US-based MSO in the media and communications sector and a long-term deal with a global medical device OEM leveraging AI.
- Despite near-term reprioritization in EV R&D budgets by some OEMs towards ICE and hybrids, TELX remains confident in the long-term prospects of SDVs and ADAS. They continue to invest in these areas and see interest from both passenger and commercial vehicle companies.
- Employee attrition remains low at 12.4%, and the company added a net of 85 employees during the quarter.
- The strategic focus on Japan, emerging markets, and India continues
  to yield positive results. Revenue from India grew by 21.9% YoY, while
  Japan and emerging markets saw a significant growth of 66.8% YoY.
  This strong performance in these regions is expected to be beneficial
  in the coming quarters.
- TELX launched an ODC in Pune for Suzuki Motor Corporation, Japan, to accelerate software and virtual development for next-generation connected, EV, and ADAS technologies. This is a strategic initiative to support Suzuki's innovation in advanced engineering and green mobility.

## **Sequential Operating Performance**


Sequential Operating Performance						
Income Statement	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Income Statement Revenues (INR Mn)	8,817	9,142	9,059	9,265	9,551	9,392
Gross Profit (INR Mn)	3,547	3,739	3,688	3,775	3,808	3,679
Gross Margin (%)	40.2	40.9	40.7	40.7	39.9	39.2
EBIT (INR Mn)	2,388	2,447	2,337	2,252	2,393	2,206
EBIT Margin (%)	27.1	26.8	25.8	24.3	25.1	23.5
PAT (INR Mn)	2,002	2,064	1,969	1,841	2,294	1,990
Basic EPS (INR)	32.2	33.2	31.6	29.6	36.8	32.0
Operating Metrics Revenue - Geography (%)						
Americas	39.6	37.4	36.0	33.7	30.3	30.9
Europe	40.0	40.5	40.3	42.2	42.7	40.4
India	15.5	16.4	17.3	17.6	18.8	19.4
RoW	4.9	5.7	6.4	6.5	8.2	9.3
Total	100.0	100.0	100.0	100.0	100.0	100.0
Revenue - Segments (%)						
Embedded Product Design	86.0	86.0	-	-	-	-
Industrial Design & Visualization	11.3	11.3	-	-	-	-
Software and Design Service	-	-	97.2	97.0	97.1	97.5
System Integration & Support	2.7	2.7	2.8	3.0	2.9	2.5
Total	100.0	100.0	100.0	100.0	100.0	100.0
EPD Revenue - Industry (%)						
Transportation	46.2	46.5	51.4	52.8	55.7	55.0
Media & Communications	38.4	37.8	33.6	33.3	31.8	32.4
Healthcare & Medical Devices	15.4	15.7	14.1	13.2	11.5	11.8
Others	-	-	0.9	0.7	1.0	0.8
Total	100.0	100.0	100.0	100.0	100.0	100.0
EPD Revenue - Contract Type (%)						
Time & Material	49.7	50.0	52.1	49.1	49.5	48.1
Fixed Price	50.3	50.0	47.9	50.9	50.5	51.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
EPD Revenue - Effort Mix (%)						
Onsite	25.8	25.3	26.3	27.2	25.3	25.8
Offshore	74.2	74.7	73.7	72.8	74.7	74.2
Source: Company, CEBPL Total	100.0	100.0	100.0	100.0	100.0	100.0
Employee Metrics						
Total Headcount	12,871	13,221	13,399	13,142	12,793	12,878
Attrition Rate LTM (%)	13.7	12.9	12.4	12.3	12.5	12.4

#### Decline in revenue growth amid delay in deal ramp-ups



Source: Company, CEBPL

## Revenue expected to grow at 9.8% CAGR over FY25E-27E




Source: Company, CEBPL

#### EBIT Margins declined amid wage hike and adverse forex impact




Source: Company, CEBPL

## EBIT expected to grow at 14.8% CAGR over FY25E-27E




Source: Company, CEBPL

#### PAT decreased sequentially due to low other income




Source: Company, CEBPL

## PAT to grow at 12.2% CAGR over FY25E-27E




#### Americas and Europe markets remained weak




Source: Company, CEBPL

## Growth led by Healthcare industry




Source: Company, CEBPL

#### Attrition remained flattish; Net headcount increased




Source: Company, CEBPL

#### **Onsite and Offshore mix**




#### Segmental performance mix



Source: Company, CEBPL

## 1 Year Forward PE Band



## **Income Statement**

Income Statement (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	31,447	35,521	37,742	40,505	45,517
Gross profit	13,607	14,471	15,010	16,477	18,741
EBITDA	9,613	10,467	10,208	11,616	13,325
Depreciation	814	994	1,069	1,134	1,274
EBIT	8,799	9,472	9,140	10,482	12,050
Other income	738	1,219	1,734	1,580	1,625
Interest expense	162	203	201	223	273
PAT	7,553	7,925	8,077	8,879	10,164
EPS (INR)	121.3	127.2	129.7	142.6	163.2

Source: Company, CEBPL

# **Balance Sheet**

Balance Sheet (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
Tangible fixed assets	1,667	1,944	2,211	2,543	2,924
Goodwill & intangible assets	1,739	2,037	2,037	2,037	2,037
Investments	_	_	_	_	_
Cash & Cash equivalents	11,916	13,571	15,107	16,695	18,798
Other non-current assets	1,094	2,521	2,647	2,780	2,919
Other current assets	11,219	11,796	12,374	12,993	13,643
Total assets	27,634	31,870	34,377	37,047	40,321
Shareholder's funds	20,858	25,057	27,480	30,143	33,193
Borrowings	_	_	_	-	_
Lease liabilities	1,823	2,240	2,240	2,240	2,240
Other non-current liabilities	455	542	505	531	592
Other current liabilities	4,500	4,031	4,152	4,133	4,296
Total equity & liabilities	27,635	31,870	34,377	37,047	40,321

Cash Flows (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
Cash Flows from Operations	6,717	9,592	8,976	10,229	12,086
Cash Flows from Investing	(2,019)	(2,701)	399	114	119
Cash Flows from financing	(3,031)	(4,278)	(5,855)	(6,439)	(7,388)

Ratio Analysis	FY23	FY24	FY25E	FY26E	FY27E
Growth Ratios (%)					
Revenues	27.3	13.0	6.3	7.3	12.4
Gross Profit	28.8	6.4	3.7	9.8	13.7
EBITDA	25.5	8.9	-2.5	13.8	14.7
EBIT	23.9	7.6	-3.5	14.7	15.0
Margin Ratios (%)					
Gross Profit Margin	43.3	40.7	39.8	40.7	41.2
EBITDA Margin	30.6	29.5	27.0	28.7	29.3
EBIT Margin	28.0	26.7	24.2	25.9	26.5
Profitability (%)					
ROE	36.2	31.6	29.4	29.5	30.6
ROIC	59.6	49.2	45.0	47.7	51.1
ROCE	38.0	34.0	30.2	31.8	33.5
Valuation					
OCF / Net profit (%)	64.5	88.5	79.0	81.9	85.6
Book Value Per Share (x)	335.0	402.3	441.2	484.0	533.0
Free Cash Flow Yield (%)	1.1	1.5	1.3	2.1	2.1

## **Historical Price Chart: TATA Elxsi Limited**



Institutional Research Team			
Utsav Verma, CFA	Head of Research – Institutional Equities	utsav.verma@choiceindia.com	+91 22 6707 9440
Prashanth Kumar Kota, CFA	Analyst – Basic Materials / Real Estate & Infra	prashanth.kota@choiceindia.com	+91 22 6707 9887
Deepika Murarka	Analyst – Pharmaceuticals / Healthcare	deepika.murarka@choiceindia.com	+91 22 6707 9513
Ashutosh Murarka	Analyst – Cement	ashutosh.murarka@choiceindia.com	+91 22 6707 9887
Putta Ravi Kumar	Analyst – Defense	ravi.putta@choiceindia.com	+91 22 6707 9908
Aayush Saboo	Analyst – Real Estate & Infrastructure	aayush.saboo@choiceindia.com	+91 22 6707 9512
Maitri Sheth	Analyst – Pharmaceuticals / Healthcare	maitri.sheth@choiceindia.com	+91 22 6707 9511
Nikhil Kamble	Sr. Associate – Consumer Retail	nikhil.kamble@choiceindia.com	+91 22 6707 9513
Bharat Kumar Kudikyala	Associate – Building Material	bharat.kudikyala@choiceindia.com	+91 22 6707 9887
Vinay Rawal	Associate – SMID	vinay.rawal@choiceindia.com	+91 22 6707 9887
Heet Chheda	Associate – Automobile	heet.chheda@choiceindia.com	+91 22 6707 9952
Aryan Goyal	Associate – Automobile	aryan.goyal@choiceindia.com	+91 22 6707 9517
Rushil Katiyar	Associate – Information Technology	rushil.katiyar@choiceindia.com	+91 22 6707 9887

#### **CHOICE RATING DISTRIBUTION & METHODOLOGY**

BUY The security is expected to generate upside of 15% or more over the next 12 months

HOLD The security is expected to show upside or downside returns by 14% to -5% over the next 12 months

SELL The security is expected to show downside of 5% or more over the next 12 months

## Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id - Prashant.salain@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited. The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein.

Institutional Equities Choice

These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Past performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

#### Disclosures of Interest (Additional):

- "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. "CEBPL" its research Analyst, or its associates or relatives of the research analyst affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- 4. "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- "CEBPL, or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 8. CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 9. "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. <a href="https://choiceindia.com/research-listing">https://choiceindia.com/research-listing</a>

Sr. No.	Particulars	Yes / No
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADINR) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given above.